COMPARISON OF THE PHARMACOKINETICS BETWEEN TWO VORICONAZOLE FORMULATIONS AND THE EFFECT OF CYP2C19 POLYMORPHISMS ON VORICONAZOLE EXPOSURE.

Lee J.; Han H.; Shin D.; Cho J.; Jang I.; Lim K.; Yu K.; Shin S.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >COMPARISON OF THE PHARMACOKINETICS BETWEEN TWO VORICONAZOLE FORMULATIONS AND THE EFFECT OF CYP2C19 POLYMORPHISMS ON VORICONAZOLE EXPOSURE.

【24h】

COMPARISON OF THE PHARMACOKINETICS BETWEEN TWO VORICONAZOLE FORMULATIONS AND THE EFFECT OF CYP2C19 POLYMORPHISMS ON VORICONAZOLE EXPOSURE.

机译：两种伏立康唑制剂的药代动力学比较和CYP2C19多态性对伏立康唑暴露的影响。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2014年第1期|共1页
作者
Lee J.; Han H.; Shin D.; Cho J.; Jang I.; Lim K.; Yu K.; Shin S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. COMPARISON OF THE PHARMACOKINETICS BETWEEN TWO VORICONAZOLE FORMULATIONS AND THE EFFECT OF CYP2C19 POLYMORPHISMS ON VORICONAZOLE EXPOSURE. [J] . Lee J., Han H., Shin D., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：两种伏立康唑制剂的药代动力学比较和CYP2C19多态性对伏立康唑暴露的影响。
2. Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole [J] . Walsh T. J., Moriyama B., Penzak S. R., Clinical Pharmacology and Therapeutics . 2017,第2期

机译：反应“伏立康唑的药物生物：CYP2C19，但也需要进行基因分型” - CYP3A4和CYP3A5多态性在Voriconazole的临床药代动力学中的作用
3. Population pharmacokinetics of voriconazole and CYP2C19 CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients [J] . Lin Xiao‐bin, Li Zi‐wei, Yan Miao, British Journal of Clinical Pharmacology . 2018,第7期

机译：用于优化肾移植受者的剂量方案的voriconazole和Cyp2C19 Cyp2C19多态性的人口药代动力学
4. Decreased Urinary Excretion of Hydroxylated Metabolites of Voriconazole in CYP2C19 Poor Metabolizers [C] . Joo-Youn Cho, Hyang Hee Yang, Seo Hyun Yoon, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：降低CYP2C19贫困代谢物中voriconazole的羟基化代谢物的尿液排泄
5. Pharmacokinetics of voriconazole in horses and alpacas. [D] . Chan, Hui Min. 2008

机译：伏立康唑在马和羊驼中的药代动力学。
6. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles [O] . Hyewon Chung, Howard Lee, HyeKyung Han, 2015

机译：两种伏立康唑制剂的药代动力学比较以及CYP2C19多态性对其药代动力学特征的影响
7. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles [O] . Hyewon Chung, Howard Lee, HyeKyung Han, 2015

机译：两种伏立康唑制剂的药代动力学比较及CYP2C19多态性对其药代动力学谱的影响

COMPARISON OF THE PHARMACOKINETICS BETWEEN TWO VORICONAZOLE FORMULATIONS AND THE EFFECT OF CYP2C19 POLYMORPHISMS ON VORICONAZOLE EXPOSURE.

著录项

相似文献

相关主题

期刊订阅